ecDNA research moves from lab concept to first clinical trials
Start here
Stanford physician-scientist Paul Mischel, whose father died of stomach cancer, has built a research program around extrachromosomal DNA (ecDNA): circular pieces of DNA that carry oncogenes outside chromosomes, breaking conventional rules of genetic inheritance. Because cancer cells can rapidly remodel their genomes through ecDNA, they can resist therapies including precision oncology and immunotherapy. The work has now moved from concept toward clinical translation, with the first drugs targeting ecDNA already in clinical trials.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- youtube.comPaul Mischel explains how ecDNA drives cancer treatment resistance and enters clinical testing
Stanford physician-scientist Paul Mischel, motivated by his father's death from stomach cancer, describes how oncogenes can jump from chromosomes onto circular extrachromosomal DNA (ecDNA), breaking conventional rules of genetic inheritance. ecDNA lets cancer cells remodel their genomes rapidly enough to resist therapies, including precision oncology and immunotherapy. The first drugs targeting ecDNA are already being tested in clinical trials, moving the work from concept toward clinical translation.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 18 04:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.